Use of N-acetylcysteine in the management of coronary artery diseases.
Thrombolysis after acute myocardial infarction may lead to a number of adverse effects (reperfusion injury) such as myocardial stunning, arrhythmias and even myocardial damage and extension of the infarct size. Some recent clinical studies have demonstrated that the intravenous infusion of N-acetylcysteine during thrombolysis was associated with a decrease in infarct size and better preservation of left ventricular function, probably due to antioxidant and free radical scavenger properties of N-acetylcysteine. Short- and long-term studies indicated that also in patients with unstable angina pectoris and threat of infarct, the intravenous or oral administration of N-acetylcysteine in association with nitroglycerin is highly effective in decreasing the risk of worsening, mainly by preventing the occurrence of acute myocardial infarction.
Marchetti
G
G
Direzione Medica Zambon Italia, Milano.
Lodola
E
E
Licciardello
L
L
Colombo
A
A
D000111:Acetylcysteine / Q000009:adverse effects / Q000627:therapeutic use*; D000789:Angina, Unstable / Q000188:drug therapy; D000818:Animals; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D016166:Free Radical Scavengers / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D005996:Nitroglycerin / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
D016166:Free Radical Scavengers; D014665:Vasodilator Agents; D005996:Nitroglycerin; D000111:Acetylcysteine